← brief for 2026-09-16 · Slowing decline

Fragility metrics are the wrong tool for finerenone's cardiovascular evidence.

Key takeaways

This is a short opinion letter about finerenone, a drug used to protect the heart and kidneys in some people with diabetes and kidney disease. The authors argue that the "fragility index" is the wrong way to judge the heart benefits seen in finerenone trials. That index is a number meant to show how easily a trial's result could flip. The letter has no new results. It is a debate about statistics, not new evidence for or against the drug.

Who did this work

Biswas S · Srivastava Y · Bandaru SK

Source

Article · PubMed, the drug frontier · 2026 Sep 16
https://pubmed.ncbi.nlm.nih.gov/42747354/